keyword
MENU ▼
Read by QxMD icon Read
search

Long term effects corticosteroids ad

keyword
https://www.readbyqxmd.com/read/29620611/bleach-for-atopic-dermatitis-beyond-antimicrobials
#1
Melody Maarouf, Vivian Y Shi
Individuals with atopic dermatitis (AD) have used bleach baths to treat superinfections, although their mechanism of action is not well understood. The ClinicalTrials.gov, National Eczema Association, and PubMed databases were searched for studies that investigate the role bleach plays in modulating AD. Fifteen studies were included in this review. Bleach bath improves clinical symptoms of AD and restores surface microbiome by eradicating bacteria, most notably Staphylococcus aureus. Many studies have noted that this antimicrobial effect has reduced the need for topical corticosteroids or topical antibiotics...
April 3, 2018: Dermatitis
https://www.readbyqxmd.com/read/29587693/a-case-of-allergic-bronchopulmonary-aspergillosis-successfully-treated-with-mepolizumab
#2
Takeshi Terashima, Taro Shinozaki, Eri Iwami, Takahiro Nakajima, Tatsu Matsuzaki
BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease comprising a complex hypersensitivity reaction to Aspergillus fumigatus. Clinical features of ABPA are wheezing, mucoid impaction, and pulmonary infiltrates. Oral corticosteroids and anti-fungal agents are standard therapy for ABPA, but long-term use of systemic corticosteroids often causes serious side effects. CASE PRESENTATION: A 64-year-old woman was diagnosed with ABPA based on a history of bronchial asthma (from 40 years of age), elevated total IgE, the presence of serum precipitating antibodies and elevated specific IgE antibody to A...
March 27, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29471919/dupilumab-a-review-of-its-use-in-the-treatment-of-atopic-dermatitis
#3
Melinda J Gooderham, H Chih-Ho Hong, Panteha Eshtiaghi, Kim A Papp
Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD...
March 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29416367/profile-of-dupilumab-and-its-potential-in-the-treatment-of-inadequately-controlled-moderate-to-severe-atopic-dermatitis
#4
REVIEW
Olabola Awosika, Lori Kim, Momina Mazhar, Monica Rengifo-Pardo, Alison Ehrlich
Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13...
2018: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/29373242/fluticasone-in-mild-to-moderate-atopic-dermatitis-relapse-a-randomized-controlled-trial
#5
E Rubio-Gomis, I Martinez-Mir, F J Morales-Olivas, A Martorell-Aragones, V Palop-Larrea, A Bernalte-Sesé, J C Cerda-Mir, P Polo-Martín, I Febrer, L Aranda-Grau, I Llosa-Cortes, Mª J Tejedor-Sanz, J C Julia-Benito, T Alvarez-de-Laviada-Mulero, Mª V Planelles-Cantarino, E Apolinar-Valiente, M Loriente-Tur, A M Abella-Bazataqui, I Alvarez-Gonzalez, C Morales-Carpi, Mª E Burches-Greus, A B Ferrer-Bautista, R Felix-Toledo, D Marmaneu-Laguia, V E Garcia-Martinez, Mª A Beltran-Marques, B Rodriguez-Gracia
BACKGROUND: The long-term efficacy of corticosteroids to prevent atopic dermatitis (AD) relapses has partially been addressed in children. This study compared an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% with its vehicle base in reducing the risk of relapse in children with stabilized AD. METHODS: A randomized controlled, multicentric, double-blind trial was conducted. Children (2-10 years) with mild/moderate AD (exclusion criteria: >30% affected body surface area and/or head) were enrolled into an Open-label Stabilization Phase (OSP) of up to 2 weeks on twice daily FP...
January 17, 2018: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29317770/corticosteroid-sparing-in-inflammatory-bowel-disease-is-more-often-achieved-in-the-immunomodulator-and-biological-era-results-from-the-dutch-population-based-ibdsl-cohort
#6
Steven F G Jeuring, Vince B C Biemans, Tim R A van den Heuvel, Maurice P Zeegers, Wim H Hameeteman, Mariëlle J L Romberg-Camps, Liekele E Oostenbrug, Ad A M Masclee, Daisy M A E Jonkers, Marieke J Pierik
OBJECTIVES: Corticosteroid-free remission is an emerging treatment goal in the management of inflammatory bowel disease (IBD). In the population-based Inflammatory Bowel Disease South Limburg cohort, we studied temporal changes in corticosteroid use and assessed the corticosteroid-sparing effects of immunomodulators and biologicals in real life. METHODS: In total, 2,823 newly diagnosed patients with Crohn's disease (CD) or ulcerative colitis (UC) were included. Corticosteroid exposure and cumulative days of use were compared between patients diagnosed in 1991-1998 (CD: n=316, UC: n=539), 1999-2005 (CD: n=387, UC: n=527), and 2006-2011 (CD: n=459, UC: n=595)...
March 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29315479/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and-concomitant-topical-corticosteroids-liberty-ad-chronos-a-critical-appraisal
#7
J Thomson, A G H Wernham, H C Williams
AIM: Blauvelt et al. aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) vs. placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD). SETTING AND DESIGN: This multicentre randomized, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions across 161 sites in 14 countries. STUDY EXPOSURE: Adults with moderate-to-severe AD were randomly assigned (3: 1: 3) to receive subcutaneous dupilumab 300 mg once weekly plus TCS, dupilumab 300 mg every 2 weeks plus TCS or placebo plus TCS until week 52...
January 6, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29258789/evaluation-of-potential-continuation-rules-for-mepolizumab-treatment-of-severe-eosinophilic-asthma
#8
Necdet B Gunsoy, Sarah M Cockle, Steven W Yancey, Oliver N Keene, Eric S Bradford, Frank C Albers, Ian D Pavord
BACKGROUND: Mepolizumab significantly reduces exacerbations in patients with severe eosinophilic asthma. The early identification of patients likely to receive long-term benefit from treatment could ensure effective resource allocation. OBJECTIVE: To assess potential continuation rules for mepolizumab in addition to initiation criteria defined as 2 or more exacerbations in the previous year and blood eosinophil counts of 150 cells/μL or more at initiation or 300 cells/μL or more in the previous year...
December 16, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29248522/phosphodiesterase-4-inhibitors
#9
Rema Zebda, Amy S Paller
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited their use. More targeted options with fewer systemic and cutaneous side effects are needed for treating AD. Phosphodiesterase 4 (PDE4) is involved in the regulation of proinflammatory cytokines via the degradation of cyclic adenosine monophosphate...
March 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29181960/a-starch-glycyrretinic-zinc-oxide-and-bisabolol-based-cream-in-the-treatment-of-chronic-mild-to-moderate-atopic-dermatitis-in-children-a-three-center-assessor-blinded-trial
#10
Amelia Licari, Giulia Ruffinazzi, Maria DE Filippo, Riccardo Castagnoli, Alessia Marseglia, Fabio Agostinis, Mario Puviani, Massimo Milani, Gian L Marseglia
BACKGROUND: Atopic dermatitis (AD) is a very common chronic inflammatory and eczematous skin condition characterized by flares and remissions. Skin barrier alteration or dysfunction is the most relevant patogenetic factor. Topical corticosteroids are the mainstay treatment of AD, especially during flare periods. The daily use of emollients and moisturizers is also considered a relevant adjunctive strategy to improve skin barrier function and skin appearance in AD patients. Long-term use of topical corticosteroids is associated with important drawbacks and side effects...
December 2017: Minerva Pediatrica
https://www.readbyqxmd.com/read/29124712/safety-and-efficacy-of-phototherapy-in-the-management-of-eczema
#11
Annalisa Patrizi, Beatrice Raone, Giulia Maria Ravaioli
Atopic Dermatitis (AD), a common skin disease, can occur in patients of all age, gender and ethnicity. It is an inflammatory affection, characterized by chronic and highly debilitating behavior. First-line interventions against AD include environmental measures and topical emollients, corticosteroids or calcineurin inhibitors. When these measures are not sufficient, phototherapy represents an efficient second-line option of treatment; it can be administered on its own, or in the most severe cases combined with systemic medicaments such as corticosteroids...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29042806/feeding-filaggrin-effects-of-l-histidine-supplementation-in-atopic-dermatitis
#12
Siao Pei Tan, Simon B Brown, Christopher Em Griffiths, Richard B Weller, Neil K Gibbs
Atopic dermatitis (AD), also known as eczema, is one of the most common chronic skin conditions worldwide, affecting up to 16% of children and 10% of adults. It is incurable and has significant psychosocial and economic impacts on the affected individuals. AD etiology has been linked to deficiencies in the skin barrier protein, filaggrin. In mammalian skin, l-histidine is rapidly incorporated into filaggrin. Subsequent filaggrin proteolysis releases l-histidine as an important natural moisturizing factor (NMF)...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/29029618/balneotherapeutic-effects-of-high-mineral-spring-water-on-the-atopic-dermatitis-like-inflammation-in-hairless-mice-via-immunomodulation-and-redox-balance
#13
Johny Bajgai, Ailyn Fadriquela, Jesmin Ara, Rahima Begum, Md Faruk Ahmed, Cheol-Su Kim, Soo-Ki Kim, Kwang-Yong Shim, Kyu-Jae Lee
BACKGROUND: Atopic dermatitis (AD) is a chronic relapsing allergic inflammatory skin disease that currently affects millions of children and adults worldwide. Drugs used to treat these inflammatory diseases include anti-histamines, corticosteroids and calcineurin inhibitors but these drugs have their limitations such as adverse effects with their long-term usage. Thus, researcher's interest in several alternative and complementary therapies are continually growing and balneotherapy is one of these approaches...
October 13, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28971004/short-term-mechanisms-influencing-volumetric-brain-dynamics
#14
REVIEW
Nikki Dieleman, Huiberdina L Koek, Jeroen Hendrikse
With the use of magnetic resonance imaging (MRI) and brain analysis tools, it has become possible to measure brain volume changes up to around 0.5%. Besides long-term brain changes caused by atrophy in aging or neurodegenerative disease, short-term mechanisms that influence brain volume may exist. When we focus on short-term changes of the brain, changes may be either physiological or pathological. As such determining the cause of volumetric dynamics of the brain is essential. Additionally for an accurate interpretation of longitudinal brain volume measures by means of neurodegeneration, knowledge about the short-term changes is needed...
2017: NeuroImage: Clinical
https://www.readbyqxmd.com/read/28942118/carpal-tunnel-syndrome-effectiveness-of-physical-therapy-and-electrophysical-modalities-an-updated-systematic-review-of-randomized-controlled-trials
#15
REVIEW
Bionka M Huisstede, Peter Hoogvliet, Thierry P Franke, Manon S Randsdorp, Bart W Koes
OBJECTIVE: To review scientific literature studying the effectiveness of physical therapy and electrophysical modalities for carpal tunnel syndrome (CTS). DATA SOURCES: The Cochrane Library, PubMed, Embase, CINAHL, and Physiotherapy Evidence Database. STUDY SELECTION: Two reviewers independently applied the inclusion criteria to select potential eligible studies. DATA EXTRACTION: Two reviewers independently extracted the data and assessed the methodologic quality using the Cochrane Risk of Bias Tool...
September 20, 2017: Archives of Physical Medicine and Rehabilitation
https://www.readbyqxmd.com/read/28902412/interventions-for-treating-tuberculous-pericarditis
#16
REVIEW
Charles S Wiysonge, Mpiko Ntsekhe, Lehana Thabane, Jimmy Volmink, Dumisani Majombozi, Freedom Gumedze, Shaheen Pandie, Bongani M Mayosi
BACKGROUND: Tuberculous pericarditis can impair the heart's function and cause death; long term, it can cause the membrane to fibrose and constrict causing heart failure. In addition to antituberculous chemotherapy, treatments include corticosteroids, drainage, and surgery. OBJECTIVES: To assess the effects of treatments for tuberculous pericarditis. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register (27 March 2017); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27 March 2017); and LILACS (1982 to 27 March 2017)...
September 13, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28859690/targeted-anti-staphylococcal-therapy-with-endolysins-in-atopic-dermatitis-and-the-effect-on-steroid-use-disease-severity-and-the-microbiome-study-protocol-for-a-randomized-controlled-trial-maas-trial
#17
Joan Totté, Jill de Wit, Luba Pardo, Frank Schuren, Martijn van Doorn, Suzanne Pasmans
BACKGROUND: Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S...
August 31, 2017: Trials
https://www.readbyqxmd.com/read/28789575/prescriptions-for-atopic-dermatitis-oral-corticosteroids-remain-commonplace
#18
Tiffany Alexander, Elena Maxim, Leah A Cardwell, Aneesh Chawla, Steven R Feldman
INTRODUCTION: Atopic dermatitis (AD) is a common, chronic inflammatory skin disease characterized by pruritic, often lichenified, patches and plaques. METHODS: Data were obtained from the Humana database, a large claim-based database encompassing more than 20 million patients under a commercial healthcare insurance plan. Our cohort included 39,526 subjects who saw a dermatologist for a primary ICD-9 diagnosis of atopic dermatitis (691.8) between the years of 2010 and 2015...
October 2, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28483402/doxycycline-for-outpatient-treated-acute-exacerbations-of-copd-a-randomised-double-blind-placebo-controlled-trial
#19
Patricia van Velzen, Gerben Ter Riet, Paul Bresser, Jeroen J Baars, Bob T J van den Berg, Jan W K van den Berg, Paul Brinkman, Jennece W F Dagelet, Johannes M A Daniels, Dewi R G L Groeneveld-Tjiong, René E Jonkers, Coen van Kan, Frans H Krouwels, Karin Pool, Arjan Rudolphus, Peter J Sterk, Jan M Prins
BACKGROUND: Antibiotics do not reduce mortality or short-term treatment non-response in patients receiving treatment for acute exacerbations of COPD in an outpatient setting. However, the long-term effects of antibiotics are unknown. The aim of this study was to investigate if the antibiotic doxycycline added to the oral corticosteroid prednisolone prolongs time to next exacerbation in patients with COPD receiving treatment for an exacerbation in the outpatient setting. METHODS: In this randomised double-blind placebo-controlled trial, we recruited a cohort of patients with COPD from outpatient clinics of nine teaching hospitals and three primary care centres in the Netherlands...
June 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28418334/juvenile-idiopathic-arthritis
#20
Kenan Barut, Amra Adrovic, Sezgin Şahin, Özgür Kasapçopur
Juvenile idiopathic arthritis is the most common chronic rheumatic disease of unknown aetiology in childhood and predominantly presents with peripheral arthritis. The disease is divided into several subgroups, according to demographic characteristics, clinical features, treatment modalities and disease prognosis. Systemic juvenile idiopathic arthritis, which is one of the most frequent disease subtypes, is characterized by recurrent fever and rash. Oligoarticular juvenile idiopathic arthritis, common among young female patients, is usually accompanied by anti-nuclear antibodie positivity and anterior uveitis...
April 5, 2017: Balkan Medical Journal
keyword
keyword
24799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"